Synaptotagmin XVI Inhibitors

Chemical inhibitors of Synaptotagmin XVI target various stages of the synaptic vesicle cycle to impair its function. Tetanus toxin, a protease, hinders the assembly of the SNARE complex by cleaving synaptobrevin, while Botulinum Toxin A targets SNAP-25, another SNARE component. These actions prevent the proper formation of the SNARE complex, which is essential for synaptic vesicle fusion, thereby indirectly inhibiting Synaptotagmin XVI's role in this process. Similarly, ω-Conotoxin GVIA and Tetrodotoxin interfere with upstream events that lead to the activation of Synaptotagmin XVI; ω-Conotoxin GVIA by blocking N-type calcium channels, and Tetrodotoxin by obstructing voltage-gated sodium channels. Both prevent the calcium influx necessary for Synaptotagmin XVI to trigger neurotransmitter release. Bafilomycin A1 and Concanamycin A, inhibitors of V-ATPases, disrupt vesicle acidification, an essential step for vesicle fusion, thereby indirectly impeding Synaptotagmin XVI function.

Dynasore, by inhibiting dynamin GTPase, halts vesicle scission from the plasma membrane, and ML9, by blocking myosin light-chain kinase, affects cytoskeletal organization, both of which are necessary for Synaptotagmin XVI-mediated vesicle trafficking. Endosulfan, as a GABA receptor antagonist, indirectly impedes Synaptotagmin XVI's facilitation of neurotransmitter release by inhibiting GABAergic neurotransmission. Latrunculin A and Jasplakinolide exert their effects by disrupting the actin cytoskeleton; Latrunculin A by preventing actin polymerization and Jasplakinolide by stabilizing actin filaments, both leading to an obstruction in vesicle transport, thereby inhibiting the function of Synaptotagmin XVI in synaptic vesicle exocytosis.